A follow-up study of patients with prostate cancer found improved survival rates for people using a drug from Generex, which has operations in Worcester.
The drug, AE37, is being developed by Antigen Express Inc., a Worcester-based subsidiary of Generex, for multiple types of cancer..
While a prior study showed that AE37-immunized patients had better than expected overall and disease-free survival, the current study shows that patients with the strongest immunological response did the best, said Generex. It was published in the peer reviewed journal Cancer Immunology.
AE37 is also the subject of a controlled, randomized Phase II trial to prevent recurrence in patients who have had breast cancer, the company said.
